TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16217231

Group type: EXPERIMENTAL
Intervention: Dyspnea self‐management program plus 24 supervised exercise sessions (DM‐training)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Dyspnea self‐management program plus 4 supervised exercise sessions (DM‐exposure)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Dyspnea self‐management program (DM)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: All groups (DM, DM-exposure, DM-training)
Number of subjects: 103
Study: 11956255

Group type: EXPERIMENTAL
Intervention: Screening (chest x-ray and cytology)
Number of subjects: 9192
Study: 10191795

Group type: EXPERIMENTAL
Intervention: SSA-VA Joint Initiative
Number of subjects: 6709

Group type: COMPARATOR
Intervention: Comparison HCHV sites
Number of subjects: 6709
Study: 7546497

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 108

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 108
Study: 2339081

Group type: EXPERIMENTAL
Intervention: Cholescintigraphy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous cholecystography
Number of subjects: 0
Study: 373995

Group type: EXPERIMENTAL
Intervention: Indoprofen 600 mg daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ibuprofen 1200 mg daily
Number of subjects: 24
Study: 31111678

Group type: EXPERIMENTAL
Intervention: ramucirumab as a single agent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ramucirumab plus paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: apatinib as a third-line or later treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ramucirumab plus immune checkpoint inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: apatinib in combination with cytotoxic agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: regorafenib
Number of subjects: 0
Study: 30518584

Group type: EXPERIMENTAL
Intervention: Establishment of a trauma treatment team in the experimental group
Number of subjects: 98

Group type: COMPARATOR
Intervention: Basic treatments in both experimental and control groups
Number of subjects: 98
Study: 26574958

Group type: EXPERIMENTAL
Intervention: Insulin resistance (measured by HOMA-IR)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: IGF-1
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: HOMA-IR
Number of subjects: 147
Study: 25014920

Group type: EXPERIMENTAL
Intervention: Quit attempt initiated the day after the first session
Number of subjects: 176
Study: 22174431

Group type: EXPERIMENTAL
Intervention: Aliskiren 75 mg
Number of subjects: 754

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 754

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 754

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 754
Study: 19047289

Group type: EXPERIMENTAL
Intervention: ProMACE-CytaBOM (63 patients)
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: m-BACOD (58 patients)
Number of subjects: 899

Group type: COMPARATOR
Intervention: CHOP or MACOP-B (not specified number)
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: CNS relapse
Number of subjects: 899
Study: 17961835

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg
Number of subjects: 20
Study: 15470334

Group type: EXPERIMENTAL
Intervention: Nitroflurbiprofen (100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Flurbiprofen (65 mg)
Number of subjects: 12
Study: 12042232

Group type: EXPERIMENTAL
Intervention: Nefazodone 400-600 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Paroxetine 20-40 mg/day
Number of subjects: 40
Study: 10457212

Group type: EXPERIMENTAL
Intervention: Dietary supplementation with vitamin E-rich sunflower oil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dietary supplementation with provitamin A-containing red palm oil
Number of subjects: 0
Study: 8547546

Group type: COMPARATOR
Intervention: Sodium Nitroprusside (SNP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Amrinone
Number of subjects: 20
Study: 1688499

Group type: EXPERIMENTAL
Intervention: Intravenous gammaglobulin (IV‐IgG) at a dose of 400 mg/kg for 5 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 832607

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Operation only
Number of subjects: 56
Study: 31383945

Group type: EXPERIMENTAL
Intervention: Surface measurement (SM) method
Number of subjects: 200

Group type: COMPARATOR
Intervention: Birth weight (BW) method
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Surface measurement (SM) method among BW < 1000 g
Number of subjects: 200

Group type: COMPARATOR
Intervention: Birth weight (BW) method among BW < 1000 g
Number of subjects: 200
Study: 31694493

Group type: EXPERIMENTAL
Intervention: Normal-weight central obesity measured by waist circumference
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normal-weight central obesity measured by waist-to-hip ratio
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normal-weight central obesity measured by visceral fat thickness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normal-weight central obesity measured by subcutaneous fat thickness
Number of subjects: 0
Study: 27522981

Group type: EXPERIMENTAL
Intervention: Autologous platelet gel
Number of subjects: 56

Group type: COMPARATOR
Intervention: Antiseptic ointment dressing
Number of subjects: 56
Study: 25844614

Group type: COMPARATOR
Intervention: HSP cleansing head
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HSP skin smoothing head
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HSP infusion head
Number of subjects: 0
Study: 23637110

Group type: EXPERIMENTAL
Intervention: Joint crisis plan in addition to treatment as usual (TAU)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 88
Study: 22922860

Group type: EXPERIMENTAL
Intervention: IV iron (iv sucrose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral iron (iron fumarate)
Number of subjects: 0
Study: 19252142

Group type: EXPERIMENTAL
Intervention: Strength Training (ST) 3 sessions per week for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untrained (UN) group
Number of subjects: 0
Study: 17106312

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure measurements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physician blood pressure measurements
Number of subjects: 0
Study: 15724865

Group type: EXPERIMENTAL
Intervention: Magnesium therapy (Magne B(6)R, Sanofi‐Synthelabo)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no magnesium therapy)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Magnesium therapy
Number of subjects: 53
Study: 15320920

Group type: EXPERIMENTAL
Intervention: School breakfast clubs in primary schools
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: School breakfast clubs in secondary schools
Number of subjects: 0
Study: 10022184

Group type: EXPERIMENTAL
Intervention: Etching for 60 seconds with 37% phosphoric acid
Number of subjects: 60

Group type: COMPARATOR
Intervention: Etching for 15 seconds with 37% phosphoric acid
Number of subjects: 60
Study: 7485860

Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin (0.3%)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Topical gentamicin (0.3%)
Number of subjects: 308
Study: 2404660

Group type: EXPERIMENTAL
Intervention: Combined pharmacotherapy plus cognitive-behavioral psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 0
Study: 7197978

Group type: EXPERIMENTAL
Intervention: Amezinium 10 mg i.v.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Amezinium (various p.o. doses)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Norfenefrine 10 mg i.m. and 40 mg p.o.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Dihydroergotamine 1 mg i.m. and 4 mg p.o.
Number of subjects: 33
Study: 31418881

Group type: EXPERIMENTAL
Intervention: Lidocaine 4%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 20
Study: 31699131

Group type: EXPERIMENTAL
Intervention: Combined group (15 mg/kg IV-TXA + 2 g topical TXA)
Number of subjects: 180

Group type: COMPARATOR
Intervention: IV group (15 mg/kg IV-TXA)
Number of subjects: 180
Study: 28081719

Group type: EXPERIMENTAL
Intervention: Antibiotic Prophylaxis (AP) continued
Number of subjects: 176

Group type: COMPARATOR
Intervention: Antibiotic Prophylaxis (AP) stopped
Number of subjects: 176
Study: 25618516

Group type: EXPERIMENTAL
Intervention: Variant rs1458038 near FGF5
Number of subjects: 7319

Group type: EXPERIMENTAL
Intervention: Variant rs11105378 near ATP2B1
Number of subjects: 7319

Group type: EXPERIMENTAL
Intervention: Variant rs1378942 near CSK
Number of subjects: 7319
Study: 23608160

Group type: EXPERIMENTAL
Intervention: Presence of anxiety disorder with depression, mental health-related impairment, and social support factors
Number of subjects: 0
Study: 21873796

Group type: EXPERIMENTAL
Intervention: Respiratory training and aerobic exercise for 1 year
Number of subjects: 122
Study: 19466476

Group type: EXPERIMENTAL
Intervention: Atomoxetine + Psychoeducation
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo + Psychoeducation
Number of subjects: 99
Study: 17150319

Group type: EXPERIMENTAL
Intervention: Chios mastic powder (5g daily, high-dose group)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Chios mastic solution (low-dose group)
Number of subjects: 133
Study: 15522140

Group type: EXPERIMENTAL
Intervention: Dried garlic powder tablets (10.8 mg alliin/d, corresponding to about three garlic cloves)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 11509678

Group type: EXPERIMENTAL
Intervention: methylprednisolone and chlorambucil
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: methylprednisolone/chlorambucil
Number of subjects: 3

Group type: COMPARATOR
Intervention: methylprednisolone alone
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: cyclosporine
Number of subjects: 3
Study: 9630113

Group type: EXPERIMENTAL
Intervention: Ionic low osmolar contrast media
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Nonionic low osmolar contrast media
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control (Ionic LOCM)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control (Nonionic LOCM)
Number of subjects: 210
Study: 8172149

Group type: EXPERIMENTAL
Intervention: Cholecystectomy
Number of subjects: 49

Group type: COMPARATOR
Intervention: ESWL
Number of subjects: 49
Study: 29987109

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/d
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/d plus valsartan 160 mg/d
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo plus valsartan
Number of subjects: 18
Study: 26778538

Group type: EXPERIMENTAL
Intervention: Daratumumab 16 mg/kg
Number of subjects: 106
Study: 25019209

Group type: EXPERIMENTAL
Intervention: 300 mg of RSV
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 22987836

Group type: EXPERIMENTAL
Intervention: One hour educational intervention on organ donation
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 184
Study: 19826884

Group type: EXPERIMENTAL
Intervention: HRQOL measures used in trials
Number of subjects: 24
Study: 18424367

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (no ischemic preconditioning)
Number of subjects: 61
Study: 16373894

Group type: EXPERIMENTAL
Intervention: Display group (real-time access to sensor glucose values)
Number of subjects: 91
Study: 14662573

Group type: EXPERIMENTAL
Intervention: Intervention group with child-oriented toilet training instructions and positive reinforcement (praise for defecating in diaper)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Control group with child-oriented toilet training instructions
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 406

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 406
Study: 11063393

Group type: COMPARATOR
Intervention: Chlorhexidine (CHX) mouthwash, performed twice daily for 3 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Amine fluoride/stannous fluoride (AmF/SnF2) mouthwash, performed twice daily for 3 weeks
Number of subjects: 32
Study: 8832997

Group type: EXPERIMENTAL
Intervention: Zolpidem 5 mg, 10 mg, or 15 mg at bedtime
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 19
Study: 1571987

Group type: EXPERIMENTAL
Intervention: Magnum system
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard system
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study: 3906073

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 31348286

Group type: EXPERIMENTAL
Intervention: IAI of TXA and PAI of placebo
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: IAI of placebo and PAI of TXA
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: IAI of TXA and PAI of TXA
Number of subjects: 210

Group type: COMPARATOR
Intervention: Double placebo (IAI of placebo and PAI of placebo)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Combined use of IAI and PAI of TXA
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Short-term effects
Number of subjects: 210
Study: 30217182

Group type: EXPERIMENTAL
Intervention: Nordic Walking (NW) only
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Nutritional Supplementation (INS) only
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Nordic Walking (NW) and Nutritional Supplementation (INS)
Number of subjects: 66
Study: 27154768

Group type: EXPERIMENTAL
Intervention: Familias Unidas intervention
Number of subjects: 213

Group type: COMPARATOR
Intervention: Community practice control
Number of subjects: 213
Study: 25134378

Group type: EXPERIMENTAL
Intervention: High serum procalcitonin (> 0.5 ng/mL)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Procalcitonin > 1.0 ng/mL
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High serum procalcitonin
Number of subjects: 45
Study: 21623590

Group type: EXPERIMENTAL
Intervention: SN6AD1 IOL
Number of subjects: 47

Group type: COMPARATOR
Intervention: ReZoom IOL
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: High add power IOLs
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Low add power IOLs
Number of subjects: 47

Group type: COMPARATOR
Intervention: All IOL types
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Diffractive optics and aspheric profiles
Number of subjects: 47

Group type: COMPARATOR
Intervention: All IOLs
Number of subjects: 47
Study: 21068427

Group type: EXPERIMENTAL
Intervention: Bihemispheric transcranial direct current stimulation (tDCS) with simultaneous physical/occupational therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation with simultaneous physical/occupational therapy
Number of subjects: 20
Study: 17694946

Group type: EXPERIMENTAL
Intervention: Removable superstructures according to the Marburg double crown system in GAP patients
Number of subjects: 17

Group type: COMPARATOR
Intervention: Cemented, implant-retained fixed superstructures in periodontally healthy patients
Number of subjects: 17
Study: 15619680

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Risedronate 35 mg once weekly
Number of subjects: 1053
Study: 12185609

Group type: EXPERIMENTAL
Intervention: 40 min exercise at 65% [Vdot]O(2) peak
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 60 min immersion in 39 degrees C water
Number of subjects: 4
Study: 9466021

Group type: EXPERIMENTAL
Intervention: Propofol infusion preceded by normal saline (group P, n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Propofol preceded by 2 micrograms.kg‐1 fentanyl (group PF, n = 12)
Number of subjects: 24
Study: 7629003

Group type: EXPERIMENTAL
Intervention: Uni-Dur (q24h extended-release theophylline)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Theo-Dur (q12h extended-release theophylline)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Uni-Dur
Number of subjects: 133

Group type: COMPARATOR
Intervention: Theo-Dur
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 133
Study: 2380943

Group type: EXPERIMENTAL
Intervention: Prescription information leaflets
Number of subjects: 3410

Group type: COMPARATOR
Intervention: No prescription information leaflets (Control)
Number of subjects: 3410
Study: 366143

Group type: EXPERIMENTAL
Intervention: 50 mg levamisole once weekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 150 mg levamisole once weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: 150 mg levamisole on 3 or 7 consecutive days
Number of subjects: 0
Study: 30222208

Group type: EXPERIMENTAL
Intervention: Eccentric cycling (ECC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Concentric cycling (CON)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: VO2peak improvement
Number of subjects: 24
Study: 28623500

Group type: EXPERIMENTAL
Intervention: Face mask ventilation without nasal passage occlusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Face mask ventilation with nasal passage occlusion (using a swimmer's nose clip)
Number of subjects: 0
Study: 26511693

Group type: EXPERIMENTAL
Intervention: Double-screw TBW
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional TBW
Number of subjects: 88
Study: 23864786

Group type: EXPERIMENTAL
Intervention: Amitriptyline (12.5 mg tid)
Number of subjects: 28
Study: 22009121

Group type: EXPERIMENTAL
Intervention: PGE1 treatment group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 19176454

Group type: COMPARATOR
Intervention: Sequential chemotherapy followed by radiotherapy (70 Gy total) after two cycles of cisplatin and 5‐fluorouracil, with a 50% or more reduction in primary tumor size.
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy and radiotherapy (60 Gy total) with four cycles of cisplatin and 5‐fluorouracil alternated with radiotherapy (20 Gy during the three 2‐week intervals).
Number of subjects: 450
Study: 17245803

Group type: EXPERIMENTAL
Intervention: Anthrax vaccine
Number of subjects: 1749
Study: 15792325

Group type: EXPERIMENTAL
Intervention: Iowa Case Management Project (ICMP) for Rural Drug Abuse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no case management)
Number of subjects: 0
Study: 12368673

Group type: EXPERIMENTAL
Intervention: Propranolol treatment
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: GH plus propranolol therapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: GH treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Combination GH plus propranolol therapy
Number of subjects: 56
Study: 9614361

Group type: EXPERIMENTAL
Intervention: rhIGF-I (40 micrograms/kg at 1800 h)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control night (untreated)
Number of subjects: 17
Study: 8126617

Group type: COMPARATOR
Intervention: Rice-lentil/yogurt/milk diet (group A; n = 26)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Soy formula (group B; n = 25)
Number of subjects: 51
Study: 7580222

Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 356916

Group type: EXPERIMENTAL
Intervention: melphalan-prednisone
Number of subjects: 55

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 55
Study: 30232712

Group type: EXPERIMENTAL
Intervention: AUT00063
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 27110643

Group type: EXPERIMENTAL
Intervention: Valerian 1600mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24958820

Group type: EXPERIMENTAL
Intervention: p16-positive OPC
Number of subjects: 181

Group type: COMPARATOR
Intervention: p16-negative OPC
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Distant progression
Number of subjects: 181
Study: 22867787

Group type: EXPERIMENTAL
Intervention: Bendamustine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 0
Study: 20726913

Group type: EXPERIMENTAL
Intervention: Ultrasonic irrigation with 1% sodium hypochlorite (NaOCl) for 1 min (n=35)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Intracanal medication with calcium hydroxide [Ca(OH)(2)] for 1 week (n=35)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Routine cleaning and shaping procedures (n=105)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Baseline group (n=25)
Number of subjects: 130
Study: 18612440

Group type: EXPERIMENTAL
Intervention: NT‐proBNP levels measured pre-anesthetic induction and on the 7th postoperative day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: E/Ea ratio measured pre-anesthetic induction and on the 7th postoperative day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison of NT‐proBNP and E/Ea
Number of subjects: 30
Study: 15751152

Group type: EXPERIMENTAL
Intervention: Pegvisomant (10 mg to 20 mg/day subcutaneously)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Pegvisomant
Number of subjects: 112
Study: 12418582

Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone Propionate (Salm/FP), 50/250 microg bd via Diskus
Number of subjects: 428

Group type: COMPARATOR
Intervention: Formoterol (12 microg bd) and Budesonide (800 microg bd) via separate Turbuhalers (Form+Bud)
Number of subjects: 428
Study: 10756610

Group type: EXPERIMENTAL
Intervention: Trained and supported GPs (n = 42) received the programme plus practice-based training and a support telephone call every two weeks.
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Trained GPs (n = 43) received the programme plus practice-based training in programme usage.
Number of subjects: 128

Group type: COMPARATOR
Intervention: Controls (n = 43) received the programme with written guidelines only.
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Trained and supported GPs
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Trained GPs
Number of subjects: 128

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 128
Study: 8777660

Group type: EXPERIMENTAL
Intervention: 1 ml of 25% sucrose solution
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sterile water
Number of subjects: 15